{"analyses":[{"ciLowerLimit":"0.395","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.662","estimateComment":"Hazard ratio was based on an unstratified Cox proportional hazard regression model and treatment as a factor in the model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.565","pValueComment":"P-value is from an unstratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.810","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of full range was not estimable due to lower number of participants with the event.","groupId":"OG000","lowerLimit":"12.62","upperLimit":"NA","value":"14.0"},{"comment":"The upper limit of full range was not estimable due to lower number of participants with the event.","groupId":"OG001","lowerLimit":"10.71","upperLimit":"NA","value":"20.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Duration of OR: response to first documentation of PD or relapse from CR for low-blast AML or relapse after CR or PR for HR MDS/CMML. Disease responses(HR MDS/CMML): modified IWG criteria for MDS;low-blast AML: revised IWG criteria for AML.Overall response(HR MDS/CMML)=CR,PR/HI,LB AML=CR+ Cri+PR.HR MDS/CMML-CR:≤5%myeloblasts with normal maturation of BM cell lines,≥11g/dL Hb,≥100\\*10\\^9/L plt,≥1.0\\*10\\^9/L ANC,0%blasts in peripheral blood; PR:CR criteria met except BM blasts≥50%less over pretreatment but still\\>5%; HI:hb increase(inc)≥1.5g/dL if baseline\\<11g/dL; plt inc≥30\\*10\\^9/L if baseline \\>20\\*10\\^9/L inc from\\<20\\*10\\^9/L-\\>20\\*10\\^9/L,ANC inc by100%; absolute inc of \\>0.5\\*10\\^9/L if baseline \\<100\\*10\\^9/L.LB AML-CR: morphologic leukemia-freestate \\>1.0\\*10\\^9 ANC,≥100\\*1 \\^9/Lplt, transfusion independence, no residual evidence of extramedullary leukemia; CRi:fulfill CR criteria except residual neutropenia\\<1.0\\*10\\^9/L/TTP\\<100\\*10\\^9/L; PR:all CR hematological values but\\>=50%less in BM aspirate.","dispersionType":"Full Range","groups":[{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG001","title":"Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"REP included all participants who received at least 1 dose of study drug and had a Baseline and at least 1 postbaseline disease assessment. Data is reported for overall responders.","reportingStatus":"POSTED","timeFrame":"From date of randomization until CR, PR or HI (up to approximately 5 years)","title":"Duration of Overall Response","type":"SECONDARY","unitOfMeasure":"months"}